Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

286
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
286
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

573
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
573
Skin Cancer01:30

Skin Cancer

6.4K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.4K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

813
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
813
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical versus systemic corticosteroids for drug reaction with eosinophilia and systemic symptoms syndrome: Real-world outcomes from a multicenter retrospective cohort.

Journal of the American Academy of Dermatologyยท2026
Same author

Incidence of autoimmune diseases in children with atopy treated with dupilumab.

The Journal of allergy and clinical immunologyยท2026
Same author

Outpatient care activities of inpatient dermatologists between 2013-2019 reveal unique practice patterns.

Journal of the American Academy of Dermatologyยท2026
Same author

Infantile Pyoderma Gangrenosum: A Rare and Challenging Case Presentation With an Updated Literature Review.

Pediatric dermatologyยท2025
Same author

Skin Disorders in Kidney Disease: Core Curriculum 2026.

American journal of kidney diseases : the official journal of the National Kidney Foundationยท2025
Same author

Continuous Subcutaneous Insulin Infusion (CSII)-Associated Granulomatous Suppurative Reaction inย Four Children With Type 1 Diabetes.

Pediatric dermatologyยท2025
Same journal

A Novel Retinoid and Salicylic Acid Topical Treatment for Moderate-Severe Acne.

Journal of drugs in dermatology : JDDยท2026
Same journal

INDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss.

Journal of drugs in dermatology : JDDยท2026
Same journal

A Randomized Controlled Trial Analyzing the Likeability, Usability, and In-Use Efficacy of Mineral Sunscreens Across Diverse Skin Tones.

Journal of drugs in dermatology : JDDยท2026
Same journal

Safety and Effectiveness of Two Reconstitution Volumes of Poly-L-Lactic Acid for Correction of Dรฉcolletage Wrinkles.

Journal of drugs in dermatology : JDDยท2026
Same journal

Randomized Controlled Study of Bacteriophages in Acne Reveals Efficacy and Novel Mechanism for Promoting Long-Term Skin Health.

Journal of drugs in dermatology : JDDยท2026
Same journal

Efficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne.

Journal of drugs in dermatology : JDDยท2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.7K

Low-dose Methotrexate for Vitiligo.

Anna Cristina Garza-Mayers, Daniela Kroshinsky

    Journal of Drugs in Dermatology : JDD
    |July 12, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Low-dose methotrexate with folic acid supplementation shows promise for vitiligo repigmentation. This study suggests it as a potential steroid-sparing option for patients unresponsive to other treatments.

    More Related Videos

    Studying Chronic Exposure of Mice to Ultraviolet B Radiation
    03:20

    Studying Chronic Exposure of Mice to Ultraviolet B Radiation

    Published on: August 19, 2025

    2.1K
    Minimal Erythema Dose MED Testing
    06:24

    Minimal Erythema Dose MED Testing

    Published on: May 28, 2013

    43.0K

    Related Experiment Videos

    Last Updated: Feb 26, 2026

    Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
    04:12

    Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

    Published on: January 19, 2024

    1.7K
    Studying Chronic Exposure of Mice to Ultraviolet B Radiation
    03:20

    Studying Chronic Exposure of Mice to Ultraviolet B Radiation

    Published on: August 19, 2025

    2.1K
    Minimal Erythema Dose MED Testing
    06:24

    Minimal Erythema Dose MED Testing

    Published on: May 28, 2013

    43.0K

    Area of Science:

    • Dermatology
    • Immunosuppression
    • Autoimmune Diseases

    Background:

    • Vitiligo treatment aims for repigmentation using various modalities, but success is not universal or rapid.
    • Extensive vitiligo often requires costly and time-consuming ultraviolet light therapy.
    • Systemic immunosuppressive monotherapy lacks supporting data for vitiligo.

    Observation:

    • A case series of 3 patients with vitiligo was treated with low-dose methotrexate (12.5-25 mg/week) and folic acid.
    • Treatment duration ranged from 11 to 16 months.
    • Clinically significant skin repigmentation was observed in all patients.

    Findings:

    • Repigmentation response occurred within 6 months in one patient.
    • No severe adverse effects were reported during the treatment period.
    • Low-dose methotrexate demonstrated efficacy in vitiligo repigmentation.

    Implications:

    • Presents a potential steroid-sparing therapeutic alternative for vitiligo.
    • Offers an option for patients with treatment-resistant vitiligo.
    • Addresses limitations of topical therapies and phototherapy costs/effectiveness.